Get to know our clinical trials
Clinical trial to evaluate the efficacy and safety of Bomedemstat compared to hydroxycarbamide in essential thrombocythemia.
THE MAIN OBJECTIVE IS TO COMPARE BOMEDEMSTAT WITH HYDROXYCARBAMIDE IN TERMS OF RCHD. HYPOTHESIS (H1): BOMEDEMSTAT IS SUPERIOR TO HYDROXYCARBAMIDE IN TERMS OF RCHD.
Specialist
Hematology and Hemotherapy Department
Madrid headquarters
Status
In recruitment
headquarters
Pamplona/Madrid
Technical Summary
- PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE TREATMENT-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BOMEDEMSTAT (MK-3543) COMPARED TO HYDROXYCARBAMIDE IN PARTICIPANTS WITH ESSENTIAL THROMBOCYTHEMIA WITHOUT PRIOR CYTOREDUCTIVE THERAPY.
- Code EudraCT: 2023-505232-36
- Protocol number: MK-3543-007
- Promoter: Merck Sharp & Dohme, S.A.
- Molecule/Drug: Bomedemstat vs Hidroxicarbamida
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.